Trials / Recruiting
RecruitingNCT05490719
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
A Single Arm, Phase II Clinical Study of Chemoradiationtherapy Combined With QL1706 (Anti-CTLA-4 and PD-1 Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, multi-center Phase II Study. This clinical study is an investigator-initiated clinical trial（IIT). The objective of this study is to evaluate the efficacy and safety of Chemoradiationtherapy combined with QL1706 (anti-CTLA-4 and PD-1 antibody) in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QL1706 | QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody. |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2024-09-01
- Completion
- 2025-09-01
- First posted
- 2022-08-08
- Last updated
- 2024-05-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05490719. Inclusion in this directory is not an endorsement.